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According to the National Health and Nutritional
Examination survey from 2009 to 2010, the prevalence
of obesity, defined as body mass index (BMI)>30kg/
m2 among 20 years old, is 35%.1 This is reflected
among liver transplantation (LT) recipients resulting in
a doubling of the prevalence of obesity from 16.8%
(class I, BMI 30-34kg/m259.4%; class II, BMI 35-
39kg/m255.3%; and class III, BMI40kg/
m252.1%) in 1987 to 1996 to 33% (class I, BMI 30-
34kg/m2521%; class II, BMI 35-39kg/m259%; and
class III, BMI40kg/m253%) in 2002 to 2011.2,3
Obesity as a predictor of posttransplant outcomes
has been addressed using national data.2,4,5 In one of
the older studies that examined the national data from
the Scientific Registry of Transplant Recipients (SRTR)
from 1987 to 1996, the adjusted risk of posttransplant
death at 2 years was 52% higher among obese com-
pared to nonobese LT recipients.2 Another study using
the data from the SRTR found that although severely
obese (BMI, 35-39kg/m2) and morbidly obese recipi-
ents (BMI40kg/m2) derive survival benefit from LT,5
their likelihoods of being turned down for an organ
were 10% and 16% higher, and rates of LT were 11%
and 29% lower among severely obese and morbidly
obese LT recipients, respectively.6 These results sug-
gest that current practices reflect an inherent reluc-
tance to transplant morbidly obese LT candidates. In
the most recent American Association for the Study of
Liver Disease guidelines on selection of LT candidates,
class III obesity is still considered a relative contraindi-
cation for LT despite demonstrable survival benefit
from LT in this subgroup of patients.3,5,7
Malnutrition, sarcopenia, and frailty are common
but under-recognized complications of decompensated
cirrhosis. Low BMI is one of the manifestations of mal-
nutrition and associated with poor outcomes in gen-
eral. Sarcopenia, as defined by decreased dorsal
muscle group area at the thoracic spine level (T11-T12)
or psoas muscle area measured by analytic morpho-
mics, is an important predictor of posttransplant mor-
tality.8,9 Additionally, sarcopenia among LT recipients
is also associated with increased rates of infection and
significantly higher hospital length of stay in an
adjusted analysis of 248 LT recipients.10 Englesbe
et al.,9 in a retrospective analysis of 509 LT recipients,
reported 1-year adjusted posttransplant survival of
49.7% for the LT recipients with the lowest quartile of
psoas muscle area compared to 87.0% for those with
the highest quartile of psoas muscle area.
In this issue of Liver Transplantation, Bambha
et al.3 carefully examined the impact of BMI on short-
term posttransplant outcomes using the national data
of adult LT recipients who received LT between March
2002 and September 2011 (n545,551).3 The main
results of their study reconfirmed that obesity did not
affect short-term posttransplant outcomes. However,
underweight LT recipients with BMI<18.5kg/m2 had
43% and 28% increased risk of 1-year posttransplant
death and graft failure, respectively, after adjusting for
various recipient and donor factors. These findings
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validated results from previous studies.4,5 Pelletier
et al.5 in their elegant analyses of national data from
September 2001 to December 2008 found no differ-
ence in posttransplant mortality risk across all BMIs.
However, the relative risk of posttransplant mortality
was 2-fold higher within 7 days of LT for those with
BMI<20kg/m2 compared to those with normal BMI.5
Dick et al. further examined the effect of BMI spectrum
on posttransplant mortality across 3 eras (1987 to
1992; February 1993 to 2002; March 2002 to 2007).4
Their study showed higher risk of posttransplant mor-
tality across 3 eras among patients with extremes of
BMI (<18.5 and 40kg/m2).4
One of the novel findings in the study by Bambha
et al.3 was the interaction between low BMI and low
Model for End-Stage Liver Disease (MELD) score.
Their study showed that the effect of low BMI
(<18.5kg/m2) on posttransplant mortality was accen-
tuated at low MELD scores (MELD<20). A similar
interaction was seen at the threshold MELD score of
26 (75th percentile). It would be important to know if
the interaction between low BMI and MELD score was
significant for the lowest quartile of MELD score (<13,
25th percentile). The authors failed to show any sig-
nificant associations between patient, donor, and
transplant factors and 3-month and 1-year posttrans-
plant mortality among low BMI–low MELD patients.
Low BMI–low MELD patients represented only 1%
(n5435) of the total cohort. The sample size may be
too small to show any association. Although the
authors adjusted for most of the pertinent recipients
and donor covariates, the effect of serum sodium as
well as year of transplant were not tested in the multi-
variate model. Both of these covariates are important
because of their associations with post-LT outcomes.
“Share 15” was implemented during the span of this
cohort. Era effect may have some influence on low
MELD–low BMI interaction. Donor risk index (DRI)
was independently associated with low BMI–low
MELD LT recipients.3 Data suggested that high-DRI
organs were more often transplanted into lower-
MELD recipients and vice versa. Compared to waiting
for a lower-DRI organ, the lowest-MELD category
recipients (MELD 6-8) who received high-DRI organs
experienced significantly higher posttransplant mor-
tality.11 There might be an inherent selection bias
(accepting a high-DRI organ for low-BMI recipient)
resulting in the significant interaction between low
MELD and low BMI. This may be one of the plausible
explanations for observed high posttransplant mor-
tality among low BMI–low MELD patients in Bambha
et al. study.
Frailty is another biological syndrome of decreased
reserve and resistance to stressors, resulting from
cumulative declines across multiple physiologic sys-
tems, and causing vulnerability to adverse outcomes.
Clinical assessment of frailty is performed using per-
formance and cognitive criteria, which are well estab-
lished in geriatrics literature. Frailty is associated
with increased wait-list mortality as well as post-
transplant mortality.12,13 Bambha et al.3 did not find
any association between functional status and the
short-term posttransplant outcomes in low BMI–low
MELD patients.
The risk factors associated with high BMI, including
diabetes mellitus, coronary artery disease, metabolic
syndrome, obstructive sleep apnea, and their effect on
posttransplant outcomes are well established;14 risk
factors associated with low BMI affecting posttransplant
outcomes require further investigation to better under-
stand if low BMI, sarcopenia, malnutrition, and frailty
are different entities or if significant overlap exists
between them and how the interaction(s) between them
affect wait-list and posttransplant outcomes. Our group
has shown the feasibility of a 10-week prehabilitation
program for wait-listed patients focusing on nutrition
and supervised exercise sessions in making improve-
ments in physical activity and dietary habits.15
Finally, malnutrition, sarcopenia, and frailty are
somewhat modifiable and adversely affect outcomes
including quality of life. Future studies focusing on
improving malnutrition, sarcopenia, and frailty before
transplant using targeted prehabilitation interven-
tion(s) may improve short-term and long-term post-
transplant outcomes.
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